Milestone Pharmaceuticals, Inc. Stock
Milestone Pharmaceuticals, Inc. Stock price
Key metrics
| Market capitalization | $86.61m |
| Enterprise Value | $84.94m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-52.15m |
| Free Cash Flow (TTM) Free Cash Flow | $-33.91m |
| Cash position | $55.96m |
Is Milestone Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Milestone Pharmaceuticals, Inc. Stock Analysis
Analyst Opinions
4 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:
Analyst Opinions
4 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:
Financial data from Milestone Pharmaceuticals, Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -52 -52 |
7%
7%
|
EBIT (Operating Income) EBIT | -52 -52 |
7%
7%
|
| Net Profit | -52 -52 |
6%
6%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Milestone Pharmaceuticals, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Milestone Pharmaceuticals, Inc. Stock News
Company Profile
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
| Head office | Canada |
| CEO | Joseph Oliveto |
| Employees | 33 |
| Founded | 2003 |
| Website | www.milestonepharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
